Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies
暂无分享,去创建一个
I. Flinn | B. Keyt | P. Armand | M. Leabman | M. Gordon | W. Godfrey | L. Nastoupil | A. Gopal | Daniel S. Chen | G. Hernandez | E. Budde | Ching-Fai Pang | I. Sison | S. Carroll